Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Fineline Cube Jun 30, 2026
Company Deals

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Fineline Cube Jun 30, 2026
Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Fineline Cube Jun 30, 2026
Company Drug

GenFleet’s SLS009 Receives Fast-Track and Orphan Drug Designations from U.S. FDA for Lymphoma and Leukemia

Fineline Cube Jan 11, 2024

Shanghai-based biotech GenFleet Therapeutics announced that its CDK9 inhibitor, SLS009 (GFH009), has received fast-track and...

Company Deals

GSK’s Acquisition of Aiolos Bio Bolsters Respiratory Medicine Portfolio with AIO-001

Fineline Cube Jan 10, 2024

UK pharmaceutical giant GSK plc (LON: GSK) has announced a deal to acquire Aiolos Bio,...

Company

WuXi AppTec Expands Peptide Manufacturing Capacity with Two New Plants in China

Fineline Cube Jan 10, 2024

WuXi AppTec (HKG: 2359, SHA: 603259), a leading China-based Contract Research, Development, and Manufacturing Organization...

Company Medical Device

Sino Medical Sciences’ HT Supreme Drug-Eluting Stent System Gains Market Approval in Bangladesh

Fineline Cube Jan 10, 2024

Sino Medical Sciences Technology Inc., (SHA: 688108), a Chinese medical device company, has announced that...

Company Drug

Novartis’s Cosentyx Secures Additional Indication for Psoriatic Arthritis in China

Fineline Cube Jan 10, 2024

Swiss pharmaceutical giant Novartis (SWX: NOVN) has announced that its drug Cosentyx (secukinumab), which targets...

Company Drug

Pfizer and Genmab’s Tivdak Earns Priority Review from FDA for Full Registration

Fineline Cube Jan 10, 2024

The US Food and Drug Administration (FDA) has accepted for priority review a filing from...

Company

International Society for Cell & Gene Therapy Comments on FDA’s CAR-T Investigation

Fineline Cube Jan 10, 2024

The International Society for Cell & Gene Therapy (ISCT) has published a statement addressing the...

Company Hospital

Meizhong Jiahe Medical Debuts on Hong Kong Stock Exchange Below IPO Price

Fineline Cube Jan 10, 2024

China-based Meizhong Jiahe Medical Science & Technology Development Co., Ltd has completed its initial public...

Company Drug Medical Device

AbbVie Launches Continuous Infusion Therapy for Advanced Parkinson’s Disease in EU

Fineline Cube Jan 10, 2024

AbbVie (NYSE: ABBV) has announced the launch of its dopamine replacement therapy, Produodopa (foslevodopa +...

Company Drug

OBI Pharma Gets US FDA Green Light for TROP2 Targeting ADC Cancer Therapy Clinical Study

Fineline Cube Jan 10, 2024

OBI Pharma (4174.TWO), partner to Biosion Inc., has announced that it has received approval from...

Company Deals

Bio-Link Partners with Verdot to Distribute Innovative Bioprocessing Products in China

Fineline Cube Jan 10, 2024

Bio-Link Biological Applied Technologies (Shanghai) Co., Ltd., a leading provider of life sciences industry solutions...

Company Deals

Synvida Raises Nearly RMB 200 Million in Series A Funding to Advance Clinical Studies

Fineline Cube Jan 10, 2024

Synvida, a biotech company incubated by Shanghai Pharma (HKG: 2607, SHA: 601607) and Shanghai Healthcare...

Company Deals Medical Device

Sinocare Partners with Illumina to Localize iScan Chip Scanners for Precision Health Applications

Fineline Cube Jan 10, 2024

Sinocare Inc. (SHE: 300298), a China-based company, has entered into a partnership agreement with U.S....

Company Deals

Johnson & Johnson to Acquire Ambrx Biopharma in a Deal Valued at USD 2 Billion

Fineline Cube Jan 9, 2024

Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare conglomerate, has announced its intention to...

Company Drug

MSD’s Gardasil 9 Receives NMPA Approval for Two-Dose Schedule in Younger Females

Fineline Cube Jan 9, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK), a prominent pharmaceutical company in the U.S., has...

Company Drug

Astellas’ Zolbetuximab Faces FDA Rejection Due to Manufacturing Facility Deficiencies

Fineline Cube Jan 9, 2024

The US Food and Drug Administration (FDA) has issued a rejection for a filing submitted...

Company Drug

3SBio Inc. Receives NMPA Approval for OTC Minoxidil Foam for Male Hair Loss Treatment

Fineline Cube Jan 9, 2024

3SBio Inc., a leading biopharmaceutical company based in China (HKG: 1530), has announced that it...

Company Deals

MSD to Acquire Harpoon Therapeutics for USD 680 Million, Expanding Its Oncology Pipeline

Fineline Cube Jan 9, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading U.S. pharmaceutical company, has announced its...

Company

Eli Lilly Appoints First Female Leader for China Unit with Huzur Devletsah at the Helm

Fineline Cube Jan 9, 2024

Eli Lilly and Company (NYSE: LLY), a leading pharmaceutical corporation in the U.S., has announced...

Company Drug

Jiangxi Jemincare Group Receives Clinical Trial Approvals for Two Innovative Biologics in the US and China

Fineline Cube Jan 9, 2024

Jiangxi Jemincare Group, a biopharmaceutical company based in China, has announced that it has received...

Posts pagination

1 … 440 441 442 … 688

Recent updates

  • METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company
  • Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China
  • Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline
  • Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications
  • Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.